IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Comparative Study of Efficacy and Safety of Clopidogrel Versus Prasugrel in Patient with Acute Coronary Syndrome

Author: UPLOADED BY-ADMIN, NIKI V. MODI, INDERMEET S. ANAND
Abstract: The aim of the study was to compare efficacy and safety of prasugrel, a new thienopyridine, versus clopidogrel in patient with acute coronary syndrome for this we randomly assigned 48 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 2 months. The primary efficacy end point was reduction in risk of the occurrence of cardiovascular death, myocardial infarction, or stroke & rehospitalization for recurrent Unstable Angina (Efficacy end point) and reduction in risk of haemorrhage (Safety end point). While the Secondary end points were Platelet aggregation measures. From result of our study it was observed that prasugrel was superior in terms of efficacy and safety as compared to clopidogrel except the bleeding event which was found higher in prasugrel group. Thus the superiority of both the loading dose and maintenance dose of prasugrel compared with the standard dose of clopidogrel emphasizes the benefits of high level of inhibition of platelet aggregation by P2Y12 receptor inhibition prevents the cardiac events in patient of acute coronary syndrome. The greatest risk of the more aggressive antiplatelet regimen with prasugrel is bleeding. So efforts to minimize the risk of excess bleeding with prasugrel are needed. Although our results suggest that prasugrel seems to be a better option than clopidogrel, long term studies with a larger population size and for a longer follow up duration are required to confirm the superiority of prasugrel as compared to clopidogrel in Indian patients with acute coronary syndrome.
Keyword: Acute Coronary Syndrome; Prasugrel; Clopidogrel
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free